Comparative analysis of the effectiveness of neoadjuvant systemic therapy and primary surgical treatment of patients with BRCA - associated triple-negative T1 breast cancer

Abstract

BACKGROUND: BRCA-associated triple-negative breast cancer does not only have a better overall survival rate, but also a longer recurrence-free period in compatison to patients with sporadic breast cancer. BRCA-associated triple-negative breast cancer shows high sensitivity to chemotherapeutic agents, but the benefit of systemic neoadjuvant therapy for patients with tumor size ≤T1 in triple-negative breast cancer is unclear.

AIM: The aim of the study is to determine the recurrence rate in the patients with BRCA-associated triple-negative breast cancer and to determine the recurrence rate for the group of patients with tumor size ≤T1, depending on the initial treatment.

MATERIALS AND METHODS: The study includes the data of 129 patients diagnosed with BRCA-associated triple-negative breast cancer treated in the period from 2010 to 2022 at the Department of Breast Tumors of the N.N. Petrov National Medical Research Center of Oncology. All the patients have been divided into two groups depending on the initial treatment. Group I included 93 (72.1%) patients whose treatment was started with systemic neoadjuvant therapy, group II, whose initial treatment involved surgery, included 36 (27.9%) patients.

RESULTS: In group I, the number of recurrences was 22 (23.6%), and in group II — 6 (16.6%). Depending on the pathomorphological response to systemic neoadjuvant therapy, the patients of group I have been separated: in the group of patients with a complete pathomorphological response, the number of relapses was 6 (13.3%), and in the group of patients with a partial pathomorphological response — 16 (33.3%). A comparative analysis of 2 groups with tumor size ≤T1 has shown that in group I the number of patients with tumor size ≤T1 was 11 (11.8%) cases, and in group II — 16 (44.4%). Subgroup comparative analysis in group I, taking into account tumor size ≤T1, has shown that recurrence has not been observed when a complete pathomorphological response was achieved in 8 (17.7%) patients, and in the group with partial pathomorphological response in 3 (6.25%) patients with tumor size ≤T1. A relapse has been observed in 1 (2%) case. With clinical tumor size ≤T1 (n = 16), there was no recurrence in group II.

CONCLUSIONS: Patients diagnosed with BRCA-associated triple-negative breast cancer remain at a high risk of recurrence at a later stage of the disease, but this does not apply to patients with a tumor size ≤T1 since the difference in relapse-free survival [AP1] between patients, whose treatment was started with neoadjuvant systemic therapy and patients, whose initial treatment involved surgery % with a clinical tumor size ≤T1, is not confirmed.

Keywords

BRCA1/2 mutation / triple-negative breast cancer / recurrence of breast cancer

References

[1] Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science (New York, NY). 1990;250(4988):1684–1689. DOI: 10.1126/science.2270482

[2] Hall J.M., Lee M.K., Newman B. et al. Linkage of early-onset familial breast cancer to chromosome 17q21 // Science (New York, NY). 1990. Vol. 250, No. 4988. P. 1684–1689. DOI: 10.1126/science.2270482

[3] Zlokachestvennye novoobrazovaniya v Rossii v 2020 godu (zabolevaemost’ i smertnost’). Ed. by A.D. Kaprin, V.V. Starinski, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena; 2021. 252 p. (In Russ.)

[4] Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва: МНИОИ им. П.А. Герцена, 2021. 252 с.

[5] Imyanitov EN. Nasledstvennyi rak molochnoi zhelezy. Practical oncology. 2010;11(4):258–266. (In Russ.)

[6] Имянитов Е.Н. Наследственный рак молочной железы // Практическая онкология. 2010. Т. 11, № 4. С. 258–266.

[7] Graffeo R, Livraghi L, Pagani O, et al. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat. 2016;160(3):393–410. DOI: 10.1007/s10549-016-4003-9

[8] Graffeo R., Livraghi L., Pagani O. et al. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care // Breast Cancer Res. Treat. 2016. Vol. 160, No. 3. P. 393–410. DOI: 10.1007/s10549-016-4003-9

[9] Kast K, Rhiem K, Wappenschmidt B, et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016;53(7):65–71. DOI: 10.1136/jmedgenet-2015-103672

[10] Kast K., Rhiem K., Wappenschmidt B. et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer // J. Med. Genet. 2016. Vol. 53, No. 7. P. 65–71. DOI: 10.1136/jmedgenet-2015-103672

[11] Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer — current status and future directions. Ann Oncol. 2009;20(12):1913-1927. DOI: 10.1093/annonc/mdp492

[12] Gluz O., Liedtke C., Gottschalk N. et al. Triple-negative breast cancer — current status and future directions // Ann Oncol. 2009. Vol. 20, No. 12. P. 1913–1927. DOI: 10.1093/annonc/mdp492

[13] Sokolenko AP, Preobrazhenskaya EV, Aleksakhina SN, et al. Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients. Cancer Lett. 2015;359(2):259–261. DOI: 10.1016/j.canlet.2015.01.022

[14] Sokolenko A.P., Preobrazhenskaya E.V., Aleksakhina S.N. et al. Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients // Cancer Lett. 2015. Vol. 359, No. 2. P. 259–261. DOI: 10.1016/j.canlet.2015.01.022

[15] Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. DOI: 10.1086/375033

[16] Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies // Am. J. Hum. Genet. 2003. Vol. 72, No. 5. P. 1117–1130. DOI: 10.1086/375033

[17] Antoniou AC, Gayther SA, Stratton JF, et al. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18(2):173–190. DOI: 10.1002/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R

[18] Antoniou A.C., Gayther S.A., Stratton J.F. et al. Risk models for familial ovarian and breast cancer // Genet. Epidemiol. 2000. Vol. 18, No. 2. P. 173–190. DOI: 10.1002/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R

[19] King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–646. DOI: 10.1126/science.1088759

[20] King M.C., Marks J.H., Mandell J.B.; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 // Science. 2003. Vol. 302, No. 5645. P. 643–646. DOI: 10.1126/science.1088759

[21] Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–822. DOI: 10.1093/jnci/djt095

[22] Mavaddat N., Peock S., Frost D. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE // J. Natl. Cancer Inst. 2013. Vol. 105, No. 11. P. 812–822. DOI: 10.1093/jnci/djt095

[23] Zhu Y, Wu J, Zhang C, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7(43):70113–70127. DOI: 10.18632/oncotarget.12158

[24] Zhu Y., Wu J., Zhang C. et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis // Oncotarget. 2016. Vol. 7, No. 43. P. 70113–70127. DOI: 10.18632/oncotarget.12158

[25] Lee E-H, Park SK, Park B, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010;122(1):11–25. DOI: 10.1007/s10549-010-0859-2

[26] Lee E.-H., Park S.K., Park B. et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis // Breast Cancer Res. Treat. 2010. Vol. 122, No. 1. P. 11–25. DOI: 10.1007/s10549-010-0859-2

[27] Zhong Q, Peng H-L, Zhao X, et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival. a meta-analysis. Clin Cancer Res. 2015;21(1):211–220. DOI: 10.1158/1078-0432.CCR-14-1816

[28] Zhong Q., Peng H.-L., Zhao X. et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival. A meta-analysis // Clin. Cancer Res. 2015. Vol. 21, No. 1. P. 211–220. DOI: 10.1158/1078-0432.CCR-14-1816

[29] Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (New York, NY). 1994;265(5181):2088–2090. DOI: 10.1126/science.8091231

[30] Wooster R., Neuhausen S.L., Mangion J. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13 // Science (New York, NY). 1994. Vol. 265, No. 5181. P. 2088–2090. DOI: 10.1126/science.8091231

[31] Baretta Z, Mocellin S, Goldin E, et al. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(40):e4975. DOI: 10.1097/MD.0000000000004975

[32] Baretta Z., Mocellin S., Goldin E. et al. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis // Medicine (Baltimore). 2016. Vol. 95, No. 40. P. e4975. DOI: 10.1097/MD.0000000000004975

[33] Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–180. DOI: 10.1016/S1470-2045(17)30891-4

[34] Copson E.R., Maishman T.C., Tapper W.J. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study // Lancet Oncol. 2018. Vol. 19, No. 2. P. 169–180. DOI: 10.1016/S1470-2045(17)30891-4

[35] Bignon L, Fricker J, Nogues C, et al. Efficacy of anthracycline/taxanebased neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. Breast J. 2018;24(3):269–277. DOI: 10.1111/tbj.12887

[36] Bignon L., Fricker J., Nogues C. et al. Efficacy of anthracycline/taxanebased neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers // Breast J. 2018. Vol. 24, No. 3. P. 269–277. DOI: 10.1111/tbj.12887

[37] Anders CK, Winer EP, Ford JM, et al. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16(19):4702–4710. DOI: 10.1158/1078-0432.CCR-10-0939

[38] Anders C.K., Winer E.P., Ford J.M. et al. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer // Clin. Cancer Res. 2010. Vol. 16, No. 19. P. 4702–4710. DOI: 10.1158/1078-0432.CCR-10-0939

[39] Hoyer J, Vasileiou G, Uebe S, et al. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. BMC Cancer. 2018;18(1):926. DOI: 10.1186/s12885-018-4821-8

[40] Hoyer J., Vasileiou G., Uebe S. et al. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria // BMC Cancer. 2018. Vol. 18, No. 1. P. 926. DOI: 10.1186/s12885-018-4821-8

[41] Mavaddat N, Barrowdale D, Andrulis I, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134–147. DOI: 10.1158/1055-9965.EPI-11-0775

[42] Mavaddat N., Barrowdale D., Andrulis I. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) // Cancer Epidemiol. Biomarkers Prev. 2012. Vol. 21, No. 1. P. 134–147. DOI: 10.1158/1055-9965.EPI-11-0775

[43] Tsai J, Bertoni D, Hernandez-Boussard T, et al. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer. Ann Surg Oncol. 2016;23(10):3310–3316. DOI: 10.1245/s10434-016-5319-8

[44] Tsai J., Bertoni D., Hernandez-Boussard T. et al. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer // Ann. Surg. Oncol. 2016. Vol. 23, No. 10. P. 3310–3316. DOI: 10.1245/s10434-016-5319-8

[45] Singh S, Numan A, Agrawal N, et al. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. Int Immunopharmacol. 2020;83:106417. DOI: 10.1016/j.intimp.2020.106417

[46] Singh S., Numan A., Agrawal N. et al. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care // Int. Immunopharmacol. 2020. Vol. 83. P. 106417. DOI: 10.1016/j.intimp.2020.106417

[47] Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048. DOI: 10.1093/jnci/djv048

[48] Kohler B.A., Sherman R.L., Howlader N. et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state // J. Natl. Cancer Inst. 2015. Vol. 107, No. 6. P. djv048. DOI: 10.1093/jnci/djv048

[49] Geyer F, Geyer FC, Pareja F, Weigelt B, et al. The spectrum of triple-negative breast disease: High- and low- grade lesions. Am J Pathol. 2017;187(10):2139–2151. DOI: 10.1016/j.ajpath.2017.03.016

[50] Geyer F., Geyer F.C., Pareja F., Weigelt B. et al. The spectrum of triple-negative breast disease: High- and low-grade lesions // Am. J. Pathol. 2017. Vol. 187, No. 10. P. 2139–2151. DOI: 10.1016/j.ajpath.2017.03.016

[51] Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol. 2018;14(1):32–39. DOI: 10.1111/ajco.12748

[52] Khosravi-Shahi P., Cabezón-Gutiérrez L., Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies // Asia Pac. J. Clin. Oncol. 2018. Vol. 14, No. 1. P. 32–39. DOI: 10.1111/ajco.12748

[53] Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies. Cancer Cell. 2019;35(3):428–440. DOI: 10.1016/j.ccell.2019.02.001

[54] Jiang Y.Z., Ma D., Suo C. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies // Cancer Cell. 2019. Vol. 35, No. 3. P. 428–440. DOI: 10.1016/j.ccell.2019.02.001

[55] Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690. DOI: 10.1038/nrclinonc.2016.66

[56] Bianchini G., Balko J.M., Mayer I.A. et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease // Nat. Rev. Clin. Oncol. 2016. Vol. 13, No. 11. P. 674–690. DOI: 10.1038/nrclinonc.2016.66

[57] Palomba G, Budroni M, Olmeo N, et al. Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. Oncol lett. 2014;7(4):948–952. DOI: 10.3892/ol.2014.1834

[58] Palomba G., Budroni M., Olmeo N. et al. Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia // Oncol. lett. 2014. Vol. 7, No. 4. P. 948–952. DOI: 10.3892/ol.2014.1834

[59] Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–311. DOI: 10.1200/JCO.2014.57.1414

[60] Couch F.J., Hart S.N., Sharma P. et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer // J. Clin. Oncol. 2015. Vol. 33, No. 4. P. 304–311. DOI: 10.1200/JCO.2014.57.1414

[61] Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–1089. DOI: 10.1158/1078-0432.CCR-10-2560

[62] Gonzalez-Angulo A.M., Timms K.M., Liu S. et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer // Clin. Cancer Res. 2011. Vol. 17, No. 5. P. 1082–1089. DOI: 10.1158/1078-0432.CCR-10-2560

[63] Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787–2795. DOI: 10.1002/cncr.26576

[64] Hartman A.R., Kaldate R.R., Sailer L.M. et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer // Cancer. 2012. Vol. 118, No. 11. P. 2787–2795. DOI: 10.1002/cncr.26576

[65] Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5,931 Chinese women with breast cancer. Breast Cancer Res Treat. 2016;158(3):455–462. DOI: 10.1007/s10549-016-3902-0

[66] Zhang J., Sun J., Chen J. et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5,931 Chinese women with breast cancer // Breast Cancer Res. Treat. 2016. Vol. 158, No. 3. P. 455–462. DOI: 10.1007/s10549-016-3902-0

[67] Von Minckwitz G, Hahnen E, Fasching PA, et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. J Clin Oncol. 2014;32(15 suppl):1005. DOI: 10.1200/jco.2014.32.15_suppl.1005

[68] Von Minckwitz G., Hahnen E., Fasching P.A. et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto // J. Clin. Oncol. 2014. Vol. 32, No. 15 suppl. P. 1005. DOI: 10.1200/jco.2014.32.15_suppl.1005

[69] Gonzalez-Rivera M, Lobo M, Lopez-Tarruella S, et al. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Breast Cancer Res Treat. 2016;156(3):507–515. DOI: 10.1007/s10549-016-3792-1

[70] Gonzalez-Rivera M., Lobo M., Lopez-Tarruella S. et al. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial // Breast Cancer Res. Treat. 2016. Vol. 156, No. 3. P. 507–515. DOI: 10.1007/s10549-016-3792-1

[71] Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80. DOI: 10.1007/s10549-015-3293-7

[72] Wong-Brown M.W., Meldrum C.J., Carpenter J.E. et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer // Breast Cancer Res. Treat. 2015. Vol. 150, No. 1. P. 71–80. DOI: 10.1007/s10549-015-3293-7

[73] Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145(3):707–714. DOI: 10.1007/s10549-014-2980-0

[74] Sharma P., Klemp J.R., Kimler B.F. et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing // Breast Cancer Res. Treat. 2014. Vol. 145, No. 3. P. 707–714. DOI: 10.1007/s10549-014-2980-0

[75] Wang C, Chen Z, Zhou Y, et al. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes. Gland Surg. 2021;10(3):943–952. DOI: 10.21037/gs-20-762

[76] Wang C., Chen Z., Zhou Y. et al. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes // Gland Surg. 2021. Vol. 10, No. 3. P. 943–952. DOI: 10.21037/gs-20-762

RIGHTS & PERMISSIONS

Eco-Vector